RBC Life Sciences, Inc. is engaged in the marketing of nutritional supplements and personal care products through subsidiaries in North America and Southeast Asia and through licensees in Russia/Eastern Europe. The Company's segments include Nutritional Products and Medical Products. Its Nutritional Products segment distributes products in over three categories: wellness products, fitness products and personal care products. Its Medical Products segment distributes wound care products. Nutritional Products are marketed under the RBC Life brand name. As of September 30, 2015, its Nutritional Products segment manufactured and distributed a line of over 100 nutritional supplements and personal care products, including herbs, vitamins and minerals, as well as natural skin, hair and body care products. As of September 30, 2015, it marketed a line of over 35 wound care products under the MPM Medical brand name through a subsidiary operating primarily in the United States.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Related Products
- Sub-Industry: N/A
- Symbol: OTCMKTS:RBCL
- CUSIP: N/A
- Web: www.rbclifesciences.com
- Market Cap: $580,000.00
- Outstanding Shares: 2,212,000
- 50 Day Moving Avg: $0.29
- 200 Day Moving Avg: $0.28
- 52 Week Range: $0.15 - $0.70
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Annual Revenue: $24.12 million
- Price / Sales: 0.02
- Book Value: $3.63 per share
- Price / Book: 0.07
- Average Volume: 98 shs.
- Beta: -0.91
Frequently Asked Questions for RBC Life Sciences (OTCMKTS:RBCL)
What is RBC Life Sciences' stock symbol?
RBC Life Sciences trades on the OTCMKTS under the ticker symbol "RBCL."
Who are some of RBC Life Sciences' key competitors?
Some companies that are related to RBC Life Sciences include Adeptus Health (ADPT), Bayer AG (BAYRY), Caladrius Biosciences (CLBS), DNIB Unwind (BIND), Echo Therapeutics (ECTE), ELEKTA (EKTAY), Epirus Biopharmaceuticals (EPRS), Essilor International SA (ESLOY), Fresenius SE (FSNUY), Luxottica Group SpA (LUX), Mast Therapeutics (MSTX), Parnell Pharmaceuticals Holdings Ltd (PARN), Secure Point Technologies (IMSC), Sunshine Heart (SSH), Tetralogic Pharmaceuticals Corp (TLOG) and Unilife Corp (UNIS).
Who are RBC Life Sciences' key executives?
RBC Life Sciences' management team includes the folowing people:
- Clinton H. Howard, Chairman of the Board
- Steven E. Brown, President, Chief Executive Officer, Director
- Douglas Wheeler, Vice President - Operations
- Barton Dangerfield, Vice President - Marketing
- Daley L. Seeker, Chief Financial Officer, Vice President - Finance, Treasurer, Secretary
- Andrew V. Howard, Director
- Joseph P. Philipp, Independent Director
- Cynthia L. Tysinger, Independent Director
How do I buy RBC Life Sciences stock?
Shares of RBC Life Sciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is RBC Life Sciences' stock price today?
MarketBeat Community Rating for RBC Life Sciences (OTCMKTS RBCL)MarketBeat's community ratings are surveys of what our community members think about RBC Life Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of RBC Life Sciences stock can currently be purchased for approximately $0.26.
Consensus Ratings for RBC Life Sciences (OTCMKTS:RBCL) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for RBC Life Sciences (OTCMKTS:RBCL)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for RBC Life Sciences (OTCMKTS:RBCL)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for RBC Life Sciences (OTCMKTS:RBCL)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for RBC Life Sciences (OTCMKTS:RBCL)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for RBC Life Sciences (OTCMKTS:RBCL)
Insider Ownership Percentage: 45.80%Insider Trades by Quarter for RBC Life Sciences (OTCMKTS:RBCL)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|6/16/2014||Clinton H Howard||CEO||Buy||5,000||$0.60||$3,000.00|| |
|6/2/2014||Clinton H Howard||CEO||Buy||3,100||$0.60||$1,860.00|| |
Headline Trends for RBC Life Sciences (OTCMKTS:RBCL)
Latest Headlines for RBC Life Sciences (OTCMKTS:RBCL)
|RBC Life Sciences, Inc. :RBCL-US: Earnings Analysis: Q2, 2017 By the Numbers : August 17, 2017|
finance.yahoo.com - August 17 at 3:15 PM
|RBC Life Sciences, Inc. :RBCL-US: Earnings Analysis: Q1, 2017 By the Numbers : May 25, 2017|
finance.yahoo.com - May 26 at 6:21 AM
|RBC Life Sciences, Inc. Earnings Q3, 2015|
finance.yahoo.com - May 19 at 4:41 PM
|RBC Life Sciences, Inc. :RBCL-US: Earnings Analysis: Q4, 2016 By the Numbers : April 18, 2017|
finance.yahoo.com - May 19 at 4:41 PM
|RBC Life Sciences Inc. (RBCL) Lowered to Sell at ValuEngine|
www.americanbankingnews.com - May 17 at 3:26 PM
RBC Life Sciences (RBCL) Chart for Sunday, September, 24, 2017